Literature DB >> 19547885

[Cardiovascular risk markers in polycystic ovary syndrome in women with and without insulin resistance].

Wellington de Paula Martins1, Gustavo Mafaldo Soares, Carolina Sales Vieira, Rosana Maria dos Reis, Marcos Felipe Silva de Sá, Rui Alberto Ferriani.   

Abstract

PURPOSE: to evaluate whether the presence of insulin resistance (IR) alters cardiovascular risk factors in women with polycystic ovary syndrome (POS).
METHODS: transversal study where 60 POS women with ages from 18 to 35 years old, with no hormone intake, were evaluated. IR was assessed through the quantitative insulin sensitivity check index (QUICKI) and defined as QUICKI <0.33. The following variables have been compared between the groups with or without IR: anthropometric (weight, height, waist circumference, arterial blood pressure, cardiac frequency), laboratorial (homocysteine, interleucines-6, factor of tumoral-alpha necrosis, testosterone, fraction of free androgen, total cholesterol and fractions, triglycerides, C reactive protein, insulin, glucose), and ultrasonographical (distensibility and carotid intima-media thickness, dilation mediated by the brachial artery flux).
RESULTS: Eighteen women (30%) presented IR and showed significant differences in the following anthropometric markers, as compared to the women without IR (POS with and without IR respectively): body mass index (35.56+/-5.69 kg/m(2) versus 23.90+/-4.88 kg/m(2), p<0.01), waist (108.17+/-11.53 versus 79.54+/-11.12 cm, p<0.01), systolic blood pressure (128.00+/-10.80 mmHg versus 114.07+/-8.97 mmHg, p<0.01), diastolic blood pressure (83.67+/-9.63 mmHg versus 77.07+/-7.59 mmHg, p=0.01). It has also been observed significant differences in the following laboratorial markers: triglycerides (120.00+/-56.53 mg/dL versus 77.79+/-53.46 mg/dL, p=0.01), HDL (43.06+/-6.30 mg/dL versus 40.45+/-10.82 mg/dL, p=0.01), reactive C protein (7.98+/-10.54 mg/L versus 2.61+/-3.21 mg/L, p<0.01), insulin (28.01+/-18.18 microU/mL versus 5.38+/-2.48 microU/mL, p<0.01), glucose (93.56+/-10.00 mg/dL versus 87.52+/-8.75 mg/dL, p=0.02). Additionally, two out of the three ultrasonographical markers of cardiovascular risk were also different between the groups: carotid distensibility (0.24+/-0.05 mmHg-1 versus 0.30+/-0.08 mmHg-1, p<0.01) and carotid intima-media thickness (0.52+/-0.08 mm versus 0.43+/-0.09, p<0.01). Besides, the metabolic syndrome ratio was higher in women with IR (nine cases=50% versus three cases=7.1%, p<0.01).
CONCLUSIONS: POS and IR women present significant differences in several ultrasonographical, seric and anthropometric markers, which point out to higher cardiovascular risk, as compared to women without POS and IR. In face of that, the systematic IR evaluation in POS women may help to identify patients with cardiovascular risk.

Entities:  

Mesh:

Year:  2009        PMID: 19547885     DOI: 10.1590/s0100-72032009000300002

Source DB:  PubMed          Journal:  Rev Bras Ginecol Obstet        ISSN: 0100-7203


  4 in total

1.  Importance of lipid accumulation product index as a marker of CVD risk in PCOS women.

Authors:  Joelma Ximenes Prado Teixeira Nascimento; Maria Bethânia da Costa Chein; Rosângela Maria Lopes de Sousa; Alexsandro dos Santos Ferreira; Paula Andrea Navarro; Luciane Maria Oliveira Brito
Journal:  Lipids Health Dis       Date:  2015-06-24       Impact factor: 3.876

2.  Risk factors associated with metabolic syndrome and cardiovascular disease among women with polycystic ovary syndrome in Tabuk, Saudi Arabia.

Authors:  Amani Ali Shaman; Hytham Bahaeldin Mukhtar; Hyder Osman Mirghani
Journal:  Electron Physician       Date:  2017-11-25

3.  Cardiovascular Risk in Women With PCOS.

Authors:  Pietro Scicchitano; Ilaria Dentamaro; Rosa Carbonara; Gabriella Bulzis; Annamaria Dachille; Paola Caputo; Roberta Riccardi; Manuela Locorotondo; Cosimo Mandurino; Marco Matteo Ciccone
Journal:  Int J Endocrinol Metab       Date:  2012-09-30

Review 4.  Complications and challenges associated with polycystic ovary syndrome: current perspectives.

Authors:  Stefano Palomba; Susanna Santagni; Angela Falbo; Giovanni Battista La Sala
Journal:  Int J Womens Health       Date:  2015-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.